Printer Friendly

STERLING WINTHROP ANNOUNCES MAY 10 DEDICATION OF PHARMACEUTICAL R&D CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.; PAULING AND KELLEY TO SPEAK

 NEW YORK, April 27 /PRNewswire/ -- Sterling Winthrop Inc. today announced that it will dedicate its Pharmaceutical Research and Development Center, located in Upper Providence Township, Pa. (outside of Philadelphia), on Monday, May 10, 1993. The state-of-the-art facility will serve as the new U.S. headquarters of the Sterling Winthrop Pharmaceuticals Research Division's R&D efforts, which include work on innovative diagnostic imaging agents and distinctive treatments for brain and other cancers, heart disease, osteoporosis and prostate disorders, among others.
 Nobel laureate Linus Pauling, Ph.D., and William N. Kelley, M.D., chief executive officer of the University of Pennsylvania Medical Center and dean of the School of Medicine, are scheduled to be keynote speakers at the dedication ceremony, beginning at 3 p.m. on May 10. The ceremony will begin a week-long celebration which includes a scientific symposium that will feature an international delegation of scientists and dignitaries.
 "The dedication of our new pharmaceutical R&D headquarters represents another significant milestone in Sterling Winthrop's emergence as a top tier global pharmaceutical company," said Eugene Cordes, Ph.D., Sterling Winthrop vice president and president of the Sterling Winthrop Pharmaceuticals Research Division. "The facility will enable our researchers and scientists to continue their progress toward our mission: the discovery and development of distinctive pharmaceuticals that meet the health care needs of mankind."
 Construction of the $300 million facility began in October of 1990. Approximately 1 million square feet of laboratories, offices, library, auditorium and conference space has been constructed in a series of nine low-rise buildings on the 161-acre site. Scientists and support staff began moving into the site in October of 1992, and when it is complete later this year, the facility will house approximately 1,200 scientists and support personnel.
 Sterling Winthrop's pharmaceutical research and development expenditures, as a result of the company's alliance with French-based Elf Sanofi, rank among the top 12 in the industry. Sterling Winthrop Inc. is a global developer, manufacturer and marketer of pharmaceuticals and consumer health products. With headquarters in New York, Sterling Winthrop is a subsidiary of Eastman Kodak Company (NYSE: EK).
 -0- 4/27/93
 /CONTACT: Carol J. Perlman, 212-907-2724, or Terry G. Kelley, 212-907-3009, both of Sterling Winthrop/
 (EK)


CO: Sterling Winthrop Inc. ST: Pennsylvania, New York IN: MTC SU:

GK-LR -- NY108 -- 1582 04/27/93 16:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:387
Previous Article:USLIFE CORPORATION REPORTS 15 PERCENT INCREASE IN FIRST QUARTER RESULTS; COMMON STOCK DIVIDEND DECLARED
Next Article:WEST SIDE COMMUNITIES, AVENUE BANK OF OAK PARK ANNOUNCE REINVESTMENT PLAN/NEW FULL-SERVICE BRANCH
Topics:


Related Articles
STERLING WINTHROP AND SANOFI PHARMA ANNOUNCE OPERATIONS NOW UNDERWAY IN FOURTEEN MAJOR COUNTRIES; PROGRESS REPORTED IN R&D
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT OPERATIONS NOW UNDER WAY THROUGHOUT EUROPE WITH ADDITION OF SCANDINAVIAN COUNTRIES
DR. JONAS SALK, ELIE WIESEL HIGHLIGHT DEDICATION OF RPR'S RESEARCH AND CORPORATE HEADQUARTERS; AIDS BENEFIT FEATURES BACHARACH, WARWICK, FLACK
SALK, WIESEL HIGHLIGHT DEDICATION OF HEADQUARTERS FOR RHONE-POULENC RORER; BACHARACH, WARWICK, FLACK AND BOOSLER HEADLINE AIDS BENEFIT
STERLING WINTHROP DEDICATES PHARMACEUTICALS RESEARCH AND DEVELOPMENT CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.
STERLING WINTHROP SCIENCE FELLOWSHIP PROGRAM UNVEILED AT DEDICATION OF PHARMACEUTICAL RESEARCH DIVISION R&D CENTER IN UPPER PROVIDENCE TOWNSHIP
STERLING WINTHROP INC. ANNOUNCES NEW PRESIDENT AND TWO SENIOR MANAGERS FOR STERLING HEALTH EUROPE
STERLING WINTHROP INC. ANNOUNCES NEW PRESIDENT AND TWO SENIOR MANAGERS FOR STERLING HEALTH EUROPE
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
SMITHKLINE BEECHAM ACQUIRES PHARMACEUTICAL R&D FACILITY FROM EASTMAN KODAK

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters